Aspirin

• 

  Subject Areas on Research

  • 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. 
  • A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. 
  • A comparison of pharmacologic therapy with/without timely coronary intervention vs. primary percutaneous intervention early after ST-elevation myocardial infarction: the WEST (Which Early ST-elevation myocardial infarction Therapy) study. 
  • A comparison of thrombolytic therapy with operative revascularization in the initial treatment of acute peripheral arterial ischemia. 
  • A critical reappraisal of aspirin for secondary prevention in patients with ischemic heart disease. 
  • A double-blind study comparing benoxaprofen, aspirin, and benoxaprofen plus aspirin in patients with rheumatoid arthritis. 
  • A follow-up survey of clinical practices for the use of heparin, warfarin, and aspirin. 
  • A marriage of enhancement: fibrinolysis and conjunctive therapy. 
  • A narrative review of the cardiovascular risks associated with concomitant aspirin and NSAID use. 
  • A randomized factorial trial of reperfusion strategies and aspirin dosing in acute myocardial infarction. The DUCCS-II Investigators. 
  • A randomized trial of a 6-week course of celecoxib on proteinuria in diabetic kidney disease. 
  • A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. 
  • A randomized trial to compare the safety of rivaroxaban vs aspirin in addition to either clopidogrel or ticagrelor in acute coronary syndrome: The design of the GEMINI-ACS-1 phase II study. 
  • A randomized, placebo-controlled trial of enoxaparin after high-risk coronary stenting: the ATLAST trial. 
  • A validated HPLC method for the determination of pyridostigmine bromide, acetaminophen, acetylsalicylic acid and caffeine in rat plasma and urine. 
  • ASH evidence-based guidelines: should asymptomatic patients with antiphospholipid antibodies receive primary prophylaxis to prevent thrombosis? 
  • Abciximab readministration: results of the ReoPro Readministration Registry. 
  • Absolute and relative truth in clinical trials. 
  • Accelerated platelet inhibition by switching from atorvastatin to a non-CYP3A4-metabolized statin in patients with high platelet reactivity (ACCEL-STATIN) study. 
  • Acceptance of a Polypill approach to prevent cardiovascular disease among a sample of U.S. physicians. 
  • Acetylsalicylic acid and clopidogrel hyporesponsiveness following acute coronary syndromes. 
  • Acute ST-segment elevation myocardial infarction: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). 
  • Adherence to evidence-based therapies after discharge for acute coronary syndromes: an ongoing prospective, observational study. 
  • Advances in prevention and health services delivery 2010-2011. 
  • Alabama coronary artery bypass grafting Cooperative Project: baseline data. Alabama CABG Cooperative Project Study Group. 
  • Alabama coronary artery bypass grafting project: results from phase II of a statewide quality improvement initiative. 
  • An analysis of the Association of Society of Chest Pain Centers Accreditation to American College of Cardiology/American Heart Association non-ST-segment elevation myocardial infarction guideline adherence. 
  • An open-Label, 2 × 2 factorial, randomized controlled trial to evaluate the safety of apixaban vs. vitamin K antagonist and aspirin vs. placebo in patients with atrial fibrillation and acute coronary syndrome and/or percutaneous coronary intervention: Rationale and design of the AUGUSTUS trial. 
  • Analyses of coronary graft patency after aprotinin use: results from the International Multicenter Aprotinin Graft Patency Experience (IMAGE) trial. 
  • Annexin 1 induced by anti-inflammatory drugs binds to NF-kappaB and inhibits its activation: anticancer effects in vitro and in vivo. 
  • Antecedent aspirin therapy inhibits baseline platelet activity in patients presenting with acute myocardial infarction. The GUSTO-III Platelet Substudy. 
  • Anticoagulation and Antiplatelet Strategies After On-X Mechanical Aortic Valve Replacement. 
  • Antiplatelet Effect Durability of a Novel, 24-Hour, Extended-Release Prescription Formulation of Acetylsalicylic Acid in Patients With Type 2 Diabetes Mellitus. 
  • Antiplatelet agents in cardiovascular disease. 
  • Antiplatelet and anticoagulation agents in acute coronary syndromes: what is the current status and what does the future hold? 
  • Antiplatelet drug resistance and drug-drug interactions: Role of cytochrome P450 3A4. 
  • Antiplatelet drug resistance and variability in response: the role of antiplatelet therapy monitoring. 
  • Antiplatelet effects of aspirin with phytosterols: comparison with non-enteric coated aspirin alone. 
  • Antiplatelet resistance--fact or myth? 
  • Antiplatelet strategies: evaluating their current role in the setting of acute coronary syndromes. 
  • Antiplatelet therapy use after discharge among acute myocardial infarction patients with in-hospital bleeding. 
  • Antiplatelet therapy with aspirin, clopidogrel, and dipyridamole versus clopidogrel alone or aspirin and dipyridamole in patients with acute cerebral ischaemia (TARDIS): a randomised, open-label, phase 3 superiority trial. 
  • Antiplatelet therapy: What have we learned from the ANTARCTIC trial? 
  • Antiplatelet treatment for prevention of cerebrovascular events in patients with vascular diseases: a systematic review and meta-analysis. 
  • Antiplatelet treatment of cardiovascular disease: a translational research perspective. 
  • Antithrombotic Therapy After Peripheral Vascular Intervention. 
  • Antithrombotic Therapy Following CABG: For the Patient, Not the Bypass Graft. 
  • Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation. 
  • Antithrombotic effect of ticlopidine in an experimental model of retinal vein occlusion. 
  • Antithrombotic therapy during percutaneous coronary intervention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. 
  • Antithrombotic therapy for atrial fibrillation and coronary artery disease in older patients. 
  • Antithrombotic therapy for coronary artery disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. 
  • Antithrombotic therapy for non-ST-segment elevation acute coronary syndromes: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). 
  • Antithrombotic therapy in patients undergoing coronary angioplasty. 
  • Antithrombotic therapy practices in US hospitals in an era of practice guidelines. 
  • Antithrombotic therapy use at discharge and 1 year in patients with atrial fibrillation and acute stroke: results from the AVAIL Registry. 
  • Antitumor and Antiangiogenic Effects of Aspirin-PC in Ovarian Cancer. 
  • Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trial. 
  • Apixaban with antiplatelet therapy after acute coronary syndrome. 
  • Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. 
  • Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. 
  • Aspirin Resistance in healthy drug-naive men versus women (from the Heredity and Phenotype Intervention Heart Study). 
  • Aspirin and COX-2 inhibitor use in patients with stage III colon cancer. 
  • Aspirin and bleeding after coronary artery bypass grafting. 
  • Aspirin and clopidogrel resistance: consideration and management. 
  • Aspirin and dipyridamole decrease intimal hyperplasia in experimental vein grafts. 
  • Aspirin and dipyridamole inhibition of collagen-induced platelet aggregation and release in cynomolgus monkeys. 
  • Aspirin and dry eye? 
  • Aspirin and reproductive outcomes. 
  • Aspirin and the prevention of venous thromboembolism. 
  • Aspirin dose and six-month outcome after an acute coronary syndrome. 
  • Aspirin exposure reveals novel genes associated with platelet function and cardiovascular events. 
  • Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials. 
  • Aspirin for the prevention of cognitive decline in the elderly: rationale and design of a neuro-vascular imaging study (ENVIS-ion). 
  • Aspirin in cardiovascular disorders. What is the optimum dose? 
  • Aspirin in the treatment of acute myocardial infarction in elderly Medicare beneficiaries. Patterns of use and outcomes. 
  • Aspirin inhibits tumor necrosis factoralpha gene expression in murine tissue macrophages. 
  • Aspirin resistance and a single gene. 
  • Aspirin resistance. 
  • Aspirin resistance: position paper of the Working Group on Aspirin Resistance. 
  • Aspirin treatment after myocardial infarction: are health maintenance organization members, women, and the elderly undertreated? 
  • Aspirin use and outcomes in a community-based cohort of 7352 patients discharged after first hospitalization for heart failure. 
  • Aspirin use during pregnancy and hypoxia-related placental pathology. 
  • Aspirin use post-acute coronary syndromes: intolerance, bleeding and discontinuation. 
  • Aspirin, NSAIDs, and risk of prostate cancer: results from the REDUCE study. 
  • Aspirin, nonaspirin nonsteroidal anti-inflammatory drug, and acetaminophen use and risk of invasive epithelial ovarian cancer: a pooled analysis in the Ovarian Cancer Association Consortium. 
  • Aspirin-free strategies in cardiovascular disease and cardioembolic stroke prevention. 
  • Aspirin-induced hemolysis: the role of concomitant oxidant (H2O2) challenge. 
  • Aspirin-triggered resolvin D1 prevents surgery-induced cognitive decline. 
  • Aspirin: it's hard to beat. 
  • Association Between Very Low Levels of High-Density Lipoprotein Cholesterol and Long-term Outcomes of Patients With Acute Coronary Syndrome Treated Without Revascularization: Insights From the TRILOGY ACS Trial. 
  • Association between platelet receptor occupancy after eptifibatide (integrilin) therapy and patency, myocardial perfusion, and ST-segment resolution among patients with ST-segment-elevation myocardial infarction: an INTEGRITI (Integrilin and Tenecteplase in Acute Myocardial Infarction) substudy. 
  • Association of Discharge Aspirin Dose With Outcomes After Acute Myocardial Infarction: Insights From the Treatment with ADP Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome (TRANSLATE-ACS) Study. 
  • Association of US Centers for Medicare and Medicaid Services Hospital 30-Day Risk-Standardized Readmission Metric With Care Quality and Outcomes After Acute Myocardial Infarction: Findings From the National Cardiovascular Data Registry/Acute Coronary Treatment and Intervention Outcomes Network Registry-Get With the Guidelines. 
  • Association of aspirin dose and vorapaxar safety and efficacy in patients with non-ST-segment elevation acute coronary syndrome (from the TRACER Trial). 
  • Association of aspirin use and hormone receptor status with breast cancer risk. 
  • Association of aspirin use and hormone receptor status with breast cancer risk. 
  • Association of early follow-up after acute myocardial infarction with higher rates of medication use. 
  • Association of hospital myocardial infarction volume with adherence to American College of Cardiology/American Heart Association performance measures: Insights from the National Cardiovascular Data Registry. 
  • Atrial fibrillation and acute myocardial infarction: antithrombotic therapy and outcomes. 
  • Balancing the cyclooxygenase portfolio. 
  • Benefits and Risks of Extended Dual Antiplatelet Therapy After Everolimus-Eluting Stents. 
  • Biological and pharmacological aspects of perioperative hemorrhagic complications associated with oral platelet-directed antithrombotic agents. Focus on isolated coronary artery bypass grafting and oral irreversible P2Y(12) receptor antagonists. 
  • Biosignatures in thrombotic disorders. 
  • Bleeding and the use of antiplatelet agents in the management of acute coronary syndromes and atrial fibrillation. 
  • Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial. 
  • Bleeding risk following percutaneous coronary intervention in patients with diabetes prescribed dual anti-platelet therapy. 
  • Building evidence for early initiation of clopidogrel loading in non-ST-segment elevation acute coronary syndromes: going past the American College of Cardiology/American Heart Association guidelines. 
  • CASE 11-2016 Perioperative Coronary Thrombosis in a Patient With Multiple Second-Generation Drug-Eluting Stents: Is It Time for a Paradigm Shift? 
  • COX-2 polymorphism, use of nonsteroidal anti-inflammatory drugs, and risk of colon cancer in African Americans (United States). 
  • Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). 
  • Catheter thrombosis during primary percutaneous coronary intervention for acute ST elevation myocardial infarction despite subcutaneous low-molecular-weight heparin, acetylsalicylic acid, clopidogrel and abciximab pretreatment. 
  • Changes in Medical Management after Coronary CT Angiography. 
  • Changes in Medical Therapy and Lifestyle After Anatomical or Functional Testing for Coronary Artery Disease. 
  • Clinical applications of antiplatelet therapy. 
  • Clinical outcomes of palliative surgery including a systemic-to-pulmonary artery shunt in infants with cyanotic congenital heart disease: does aspirin make a difference? 
  • Clinical utility of the platelet function analyzer (PFA-100) for the assessment of the platelet status in patients with congestive heart failure (EPCOT trial). 
  • Clinically important drug-disease interactions and their prevalence in older adults. 
  • Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial. 
  • Clopidogrel and PPI interaction: clinically relevant or not? 
  • Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. 
  • Clopidogrel plus aspirin in atrial fibrillation. 
  • Clopidogrel resistance? 
  • Clopidogrel use After Myocardial Revascularization: Prevalence, Predictors, and One-Year Survival Rate. 
  • Combination antithrombotic therapies. 
  • Comparative effectiveness review of antiplatelet agents in peripheral artery disease. 
  • Comparison between ticlopidine and clopidogrel in patients undergoing primary stenting in acute myocardial infarction: results from the CADILLAC trial. 
  • Comparison of Outcomes and Costs Associated With Aspirin ± Clopidogrel After Coronary Artery Bypass Grafting. 
  • Comparison of anticoagulation regimens after Carpentier-Edwards aortic or mitral valve replacement. 
  • Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: a randomised trial. The SYMPHONY Investigators. Sibrafiban versus Aspirin to Yield Maximum Protection from Ischemic Heart Events Post-acute Coronary Syndromes. 
  • Comparison of symptoms, treatment, and outcomes of coronary artery disease among rheumatoid arthritis and matched subjects undergoing percutaneous coronary intervention. 
  • Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial. 
  • Comparison of two aspirin doses on ischemic stroke in post-myocardial infarction patients in the warfarin (Coumadin) Aspirin Reinfarction Study (CARS). 
  • Contemporary Reflections on the Safety of Long-Term Aspirin Treatment for the Secondary Prevention of Cardiovascular Disease. 
  • Contemporary patterns of discharge aspirin dosing after acute myocardial infarction in the United States: results from the National Cardiovascular Data Registry (NCDR). 
  • Controversies in oral antiplatelet therapy in patients undergoing aortocoronary bypass surgery. 
  • Coronary Thrombosis and Major Bleeding After PCI With Drug-Eluting Stents: Risk Scores From PARIS. 
  • Coronary artery disease risk reduction in HIV-infected persons: a comparative analysis. 
  • Cost-effectiveness of antiplatelet agents in secondary stroke prevention: the limits of certainty. 
  • Costs and effectiveness of ximelagatran for stroke prophylaxis in chronic atrial fibrillation. 
  • Current controversies in the use of aspirin and ticagrelor for the treatment of thrombotic events. 
  • Current evidence and clinical implications of aspirin resistance. 
  • Current perspectives on reperfusion therapy for acute ST-segment elevation myocardial infarction: integrating pharmacologic and mechanical reperfusion strategies. 
  • Current use of aspirin and antithrombotic agents in the United States among outpatients with atherothrombotic disease (from the REduction of Atherothrombosis for Continued Health [REACH] Registry). 
  • Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source. 
  • Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. 
  • Delayed thrombin-induced platelet-fibrin clot generation by clopidogrel: a new dose-related effect demonstrated by thrombelastography in patients undergoing coronary artery stenting. 
  • Depressed platelet status in an elderly patient with hemorrhagic stroke after thrombolysis for acute myocardial infarction. GUSTO-III Investigators. 
  • Design and rationale of CURRENT-OASIS 7: a randomized, 2 x 2 factorial trial evaluating optimal dosing strategies for clopidogrel and aspirin in patients with ST and non-ST-elevation acute coronary syndromes managed with an early invasive strategy. 
  • Design of Randomized, double-blind, Evaluation in secondary Stroke Prevention comparing the EfficaCy and safety of the oral Thrombin inhibitor dabigatran etexilate vs. acetylsalicylic acid in patients with Embolic Stroke of Undetermined Source (RE-SPECT ESUS). 
  • Design of the Dialysis Access Consortium (DAC) Aggrenox Prevention Of Access Stenosis Trial. 
  • Design of the Dialysis Access Consortium (DAC) Clopidogrel Prevention of Early AV Fistula Thrombosis Trial. 
  • Design, progress and challenges of a double-blind trial of warfarin versus aspirin for symptomatic intracranial arterial stenosis. 
  • Determination of platelet aggregation inhibition during percutaneous coronary intervention with the platelet function analyzer PFA-100. 
  • Diabetes mellitus, glycoprotein IIb/IIIa blockade, and heparin: evidence for a complex interaction in a multicenter trial. EPILOG Investigators. 
  • Diagnostics for aspirin resistance. 
  • Do NSAIDs interfere with the cardioprotective effects of aspirin? 
  • Do platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents?: platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents. 
  • Does Platelet Reactivity Predict Bleeding in Patients Needing Urgent Coronary Artery Bypass Grafting During Dual Antiplatelet Therapy? 
  • Does aspirin use adversely influence intermediate-term postdischarge outcomes for hospitalized patients who are treated with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers? Findings from Organized Program to Facilitate Life-Saving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). 
  • Does heart failure etiology, New York Heart Association class, or ejection fraction affect the ability of clopidogrel to inhibit heightened platelet activity? 
  • Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. 
  • Dosing and administration of ReoPro (c7E3 Fab). 
  • Dosing of clopidogrel for platelet inhibition in infants and young children: primary results of the Platelet Inhibition in Children On cLOpidogrel (PICOLO) trial. 
  • Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. 
  • Drug delivery and therapeutic impact of extended-release acetylsalicylic acid. 
  • Drug-induced interstitial lung diseases. 
  • Dual Antiplatelet Therapy and Outcomes in Patients With Atrial Fibrillation and Acute Coronary Syndromes Managed Medically Without Revascularization: Insights From the TRILOGY ACS Trial. 
  • Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation. 
  • Dual antiplatelet therapy for perioperative myocardial infarction following CABG surgery. 
  • Dual antiplatelet therapy in patients with diabetes and acute coronary syndromes managed without revascularization. 
  • Dual vs single antiplatelet therapy in patients with lower extremity peripheral artery disease - A meta-analysis. 
  • Durability of platelet inhibition by clopidogrel. 
  • Early anticoagulation of bioprosthetic aortic valves in older patients: results from the Society of Thoracic Surgeons Adult Cardiac Surgery National Database. 
  • Early statin initiation and outcomes in patients with acute coronary syndromes. 
  • Early treatment for non-ST-segment elevation acute coronary syndrome is associated with appropriate discharge care. 
  • Economic assessment of platelet glycoprotein IIb/IIIa inhibition for prevention of ischemic complications of high-risk coronary angioplasty. EPIC Investigators. 
  • Effect of Apixaban on All-Cause Death in Patients with Atrial Fibrillation: a Meta-Analysis Based on Imputed Placebo Effect. 
  • Effect of CYP2C19*2 and *3 loss-of-function alleles on platelet reactivity and adverse clinical events in East Asian acute myocardial infarction survivors treated with clopidogrel and aspirin. 
  • Effect of a Multifaceted Intervention on Use of Evidence-Based Therapies in Patients With Acute Coronary Syndromes in Brazil: The BRIDGE-ACS Randomized Trial. 
  • Effect of adjunctive dipyridamole to DAPT on platelet function profiles in stented patients with high platelet reactivity. The result of the ACCEL-DIP Study. 
  • Effect of angiotensin-converting enzyme inhibitors, beta blockers, statins, and aspirin on C-reactive protein levels in outpatients with heart failure. 
  • Effect of clopidogrel with and without aspirin on bleeding following transbronchial lung biopsy. 
  • Effect of clopidogrel with aspirin on functional outcome in TIA or minor stroke: CHANCE substudy. 
  • Effect of cyclooxygenase inhibitors and protease inhibitors on phorbol-induced stimulation of oxygen consumption and superoxide production by rat pulmonary macrophages. 
  • Effect of dipyridamole plus aspirin on hemodialysis graft patency. 
  • Effect of low-dose aspirin on thromboxane production and the antihypertensive effect of captopril. 
  • Effect of prior aspirin use on stroke severity in the trial of Org 10172 in acute stroke treatment (TOAST). 
  • Effect of prior clopidogrel use on outcomes in medically managed acute coronary syndrome patients. 
  • Effectiveness and safety of reduced-dose enoxaparin in non-ST-segment elevation acute coronary syndrome followed by antiplatelet therapy alone for percutaneous coronary intervention. 
  • Effectiveness of intermittent pulsatile elastic stockings for the prevention of calf and thigh vein thrombosis in patients undergoing elective knee surgery. 
  • Effects of clopidogrel and aspirin combination versus aspirin alone on platelet aggregation and major receptor expression in patients with heart failure: the Plavix Use for Treatment Of Congestive Heart Failure (PLUTO-CHF) trial. 
  • Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. 
  • Effects of integrelin, a platelet glycoprotein IIb/IIIa receptor antagonist, in unstable angina. A randomized multicenter trial. 
  • Effects of low-dose aspirin therapy on plasma levels of polyunsaturated fatty acids: a preliminary investigation. 
  • Effects of roxifiban on platelet aggregation and major receptor expression in patients with coronary artery disease for the Roxifiban Oral Compound Kinetics Evaluation Trial-I (ROCKET-I Platelet Substudy). 
  • Effects of vorapaxar on platelet reactivity and biomarker expression in non-ST-elevation acute coronary syndromes. The TRACER Pharmacodynamic Substudy. 
  • Efficacy and safety of angiotensin receptor blockade are not modified by aspirin in patients with chronic heart failure: a cohort study from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity (CHARM) programme. 
  • Efficacy of aspirin (325 mg) + omeprazole (40 mg) in treating coronary artery disease. 
  • Efficacy of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: one-year follow-up results of the Assessment of the Safety of a New Thrombolytic-3 (ASSENT-3) randomized trial in acute myocardial infarction. 
  • Elderly patients with acute coronary syndromes managed without revascularization: insights into the safety of long-term dual antiplatelet therapy with reduced-dose prasugrel versus standard-dose clopidogrel. 
  • Elective percutaneous coronary intervention using broad-spectrum antiplatelet therapy (eptifibatide, clopidogrel, and aspirin) alone, without scheduled unfractionated heparin or other antithrombin therapy. 
  • Endoscopic diagnosis of gastritis: causative factors in 100 patients. 
  • Enoxaparin versus unfractionated heparin in patients treated with tirofiban, aspirin and an early conservative initial management strategy: results from the A phase of the A-to-Z trial. 
  • Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study. 
  • Evaluation of platelets in heart failure: is platelet activity related to etiology, functional class, or clinical outcomes? 
  • Evidence-based therapies and mortality in patients hospitalized in December with acute myocardial infarction. 
  • Exploring Meaningful Patient Engagement in ADAPTABLE (Aspirin Dosing: A Patient-centric Trial Assessing Benefits and Long-term Effectiveness). 
  • Extended-release acetylsalicylic acid for secondary prevention of stroke and cardiovascular events. 
  • Failure of platelet parameters and biomarkers to correlate platelet function to severity and etiology of heart failure in patients enrolled in the EPCOT trial. With special reference to the Hemodyne hemostatic analyzer. Whole Blood Impedance Aggregometry for the Assessment of Platelet Function in Patients with Congestive Heart Failure. 
  • First analysis of the relation between CYP2C19 genotype and pharmacodynamics in patients treated with ticagrelor versus clopidogrel: the ONSET/OFFSET and RESPOND genotype studies. 
  • First experience with direct factor Xa inhibition in patients with stable coronary disease: a pharmacokinetic and pharmacodynamic evaluation. 
  • Focusing on inflammation in the treatment of atherosclerosis. 
  • Frequency of stent thrombosis after acute coronary syndromes (from the SYMPHONY and 2nd SYMPHONY trials). 
  • From guidelines to clinical practice: the impact of hospital and geographical characteristics on temporal trends in the management of acute coronary syndromes. The Global Registry of Acute Coronary Events (GRACE). 
  • Further ex vivo evidence supporting higher aspirin dosing in patients with coronary artery disease and diabetes. 
  • GEMINI-ACS-1: toward unearthing the antithrombotic therapy cornerstone for acute coronary syndromes. 
  • Gastrointestinal microbleeding: comparisons between benoxaprofen and other nonsteroidal antiinflammatory agents. 
  • Gene Expression Profiles Link Respiratory Viral Infection, Platelet Response to Aspirin, and Acute Myocardial Infarction. 
  • Guidelines for carotid endarterectomy. A multidisciplinary consensus statement from the ad hoc Committee, American Heart Association. 
  • Health-related quality of life outcomes with prasugrel among medically managed non-ST-segment elevation acute coronary syndrome patients: Insights from the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes (TRILOGY ACS) trial. 
  • Heparin anticoagulation in patients undergoing off-pump and on-pump coronary bypass surgery. 
  • Heparin-associated thrombocytopenia and thrombosis: a serious clinical problem and potential solution. 
  • Hepatoxicity with encephalopathy associated with aspirin therapy in rheumatoid arthritis. 
  • High platelet reactivity to multiple agonists during aspirin and clopidogrel treatment is indicative of a global hyperreactive platelet phenotype. 
  • High-dose, but not low-dose, aspirin impairs anticontractile effect of ticagrelor following ADP stimulation in rat tail artery smooth muscle cells. 
  • Higher rates of coronary angiography and revascularization following myocardial infarction may be associated with greater survival in the United States than in Canada. The CARS Investigators (Coumadin/Aspirin Reinfarction Study). 
  • Hospital variability in the rate of finding obstructive coronary artery disease at elective, diagnostic coronary angiography. 
  • Hydroxychloroquine-induced hyperpigmentation: the staining pattern. 
  • Hypercoagulability affecting early vein graft patency does not exist after off-pump coronary artery bypass. 
  • Hypolipidemic activity of tetrakis-mu-(trimethylamine-boranecarboxylato)-bis(trimethylamin e- carboxyborane)-dicopper(II) in rodents and its effect on lipid metabolism. 
  • Hypothesis formulation from subgroup analyses: nonadherence or nonsteroidal anti-inflammatory drug use explains the lack of clinical benefit of aspirin on first myocardial infarction attributed to "aspirin resistance". 
  • Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention. 
  • Impact of Anemia on Platelet Reactivity and Ischemic and Bleeding Risk: From the Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents Study. 
  • Impact of Aspirin and Clopidogrel Hyporesponsiveness in Patients Treated With Drug-Eluting Stents: 2-Year Results of a Prospective, Multicenter Registry Study. 
  • Impact of chronic antiplatelet therapy before hospitalization on ischemic and bleeding events in invasively managed patients with acute coronary syndromes: the ACUITY trial. 
  • Impact of combined pharmacologic treatment with clopidogrel and a statin on outcomes of patients with non-ST-segment elevation acute coronary syndromes: perspectives from a large multinational registry. 
  • Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial. 
  • Impact of medication therapy discontinuation on mortality after myocardial infarction. 
  • Impact of thienopyridine administration prior to primary stenting in acute myocardial infarction. 
  • Impact of time of presentation on process performance and outcomes in ST-segment-elevation myocardial infarction: a report from the American Heart Association: Mission Lifeline program. 
  • Impaired vasodilation of forearm resistance vessels in hypercholesterolemic humans. 
  • Implementation of a Regional Network for ST-Segment-Elevation Myocardial Infarction (STEMI) Care and 30-Day Mortality in a Low- to Middle-Income City in Brazil: Findings From Salvador's STEMI Registry (RESISST). 
  • Importance of measurement of platelet reactivity to ADP in patients with coronary artery disease: an historical account. 
  • In PCI-treated ACS, switching from aspirin + a newer P2Y12 blocker to aspirin + clopidogrel reduced adverse events. 
  • In-Pipeline Stenosis: Incidence, Predictors, and Clinical Outcomes. 
  • Incidence and characteristics of stroke during 90-day follow-up in patients stabilized after an acute coronary syndrome. 
  • Incidence and prognostic significance of thrombocytopenia developed during acute coronary syndrome in contemporary clinical practice. 
  • Incidence of dyspnea and assessment of cardiac and pulmonary function in patients with stable coronary artery disease receiving ticagrelor, clopidogrel, or placebo in the ONSET/OFFSET study. 
  • Incidence, Patterns, and Associations Between Dual-Antiplatelet Therapy Cessation and Risk for Adverse Events Among Patients With and Without Diabetes Mellitus Receiving Drug-Eluting Stents: Results From the PARIS Registry. 
  • Increased formation of thromboxane in vivo in humans with mastocytosis. 
  • Increased soluble platelet/endothelial cellular adhesion molecule-1 and osteonectin levels in patients with severe congestive heart failure. Independence of disease etiology, and antecedent aspirin therapy. 
  • Independent predictors of stroke in patients with atrial fibrillation: a systematic review. 
  • Inflammation and circulating endothelial progenitor cells in patients with coronary artery disease and residual platelet reactivity. 
  • Influence of Amlodipine on Haemostatic Measurements during Clopidogrel Treatment in Patients with Coronary Artery Disease. 
  • Influence of admission and discharge aspirin use on survival after primary coronary angioplasty for acute myocardial infarction. 
  • Influence of genetic polymorphisms on platelet function, response to antiplatelet drugs and clinical outcomes in patients with coronary artery disease. 
  • Influence of insurance type on the use of procedures, medications and hospital outcome in patients with unstable angina: results from the GUARANTEE Registry. Global Unstable Angina Registry and Treatment Evaluation. 
  • Influence of platelet reactivity on BARC classification in East Asian patients undergoing percutaneous coronary intervention. Results of the ACCEL-BLEED study. 
  • Influence of race and sex on thrombogenicity in a large cohort of coronary artery disease patients. 
  • Inhibited and Uninhibited Platelet Deposition Within a Thrombus: Does It Depend on the Antiplatelet Drug? 
  • Initial aspirin dose and outcome among ST-elevation myocardial infarction patients treated with fibrinolytic therapy. 
  • Integration of pharmacometabolomic and pharmacogenomic approaches reveals novel insights into antiplatelet therapy. 
  • Interaction analysis between genetic polymorphisms and pharmacodynamic effect in patients treated with adjunctive cilostazol to dual antiplatelet therapy: results of the ACCEL-TRIPLE (Accelerated Platelet Inhibition by Triple Antiplatelet Therapy According to Gene Polymorphism) study. 
  • International Expert Consensus on Switching Platelet P2Y12 Receptor-Inhibiting Therapies. 
  • Intracerebral hemorrhage after pipeline embolization: Management of antiplatelet agents and the case for point-of-care testing--case reports and review of literature. 
  • Intracranial hemorrhage in patients with atrial fibrillation receiving anticoagulation therapy. 
  • Intravenous recombinant tissue-type plasminogen activator in patients with unstable angina pectoris. Results of a placebo-controlled, randomized trial. 
  • Inverse association of anti-inflammatory treatments and Alzheimer's disease: initial results of a co-twin control study. 
  • Investigating the mechanisms of hyporesponse to antiplatelet approaches. 
  • Is aspirin associated with diabetic retinopathy? The Singapore Epidemiology of Eye Disease (SEED) study. 
  • Is aspirin intake associated with early age-related macular degeneration? The Singapore Indian Eye Study. 
  • Is rhythm-control superior to rate-control in patients with atrial fibrillation and diastolic heart failure? 
  • Ischaemic cardiac outcomes in patients with atrial fibrillation treated with vitamin K antagonism or factor Xa inhibition: results from the ROCKET AF trial. 
  • Lessons learned from a clinical trial. 
  • Letter by Moris and Avgerinos Regarding Article, "Recurrent Ischemic Lesions After Acute Atherothrombotic Stroke: Clopidogrel Plus Aspirin Versus Aspirin Alone". 
  • Letter by Moris et al Regarding Article, "Ticagrelor in Acute Stroke or Transient Ischemic Attack in Asian Patients: From the SOCRATES Trial (Acute Stroke or Transient Ischemic Attack Treated With Aspirin or Ticagrelor and Patient Outcomes)". 
  • Lifetime cost-effectiveness analysis of ticagrelor in patients with acute coronary syndromes based on the PLATO trial: a Singapore healthcare perspective. 
  • Limitations of using cardiac catheterization rates to assess the quality of care for patients with non-ST-segment elevation myocardial infarction. 
  • Long-term adherence with cardiovascular drug regimens. 
  • Long-term oral platelet glycoprotein IIb/IIIa receptor antagonism with sibrafiban after acute coronary syndromes: study design of the sibrafiban versus aspirin to yield maximum protection from ischemic heart events post-acute coronary syndromes (SYMPHONY) trial. Symphony Steering Committee. 
  • Longer-term oral antiplatelet use in stable post-myocardial infarction patients: Insights from the long Term rIsk, clinical manaGement and healthcare Resource utilization of stable coronary artery dISease (TIGRIS) observational study. 
  • Low molecular weight heparin (dalteparin) compared to unfractionated heparin as an adjunct to rt-PA (alteplase) for improvement of coronary artery patency in acute myocardial infarction-the ASSENT Plus study. 
  • Low thromboembolism and pump thrombosis with the HeartMate II left ventricular assist device: analysis of outpatient anti-coagulation. 
  • Low-dose aspirin in patients with stable cardiovascular disease: a meta-analysis. 
  • Low-dose versus high-dose aspirin after percutaneous coronary intervention: analysis from the guthrie health off-label StenT (GHOST) registry. 
  • Low-molecular-weight heparins in non-ST-segment elevation ischemia: the ESSENCE trial. Efficacy and Safety of Subcutaneous Enoxaparin versus intravenous unfractionated heparin, in non-Q-wave Coronary Events. 
  • Lung cancer chemoprevention: ACCP evidence-based clinical practice guidelines (2nd Edition). 
  • Management of Patients with Asymptomatic and Symptomatic Carotid Artery Disease: Update on Anti-Thrombotic Therapy. 
  • Management of non-Q-wave myocardial infarction. 
  • Management of patients with heparin-associated thrombocytopenia and thrombosis requiring cardiac surgery. 
  • Medical treatment for stroke prevention. 
  • Medication performance measures and mortality following acute coronary syndromes. 
  • Moderate alcohol consumption is associated with decreased platelet activity in patients presenting with acute myocardial infarction. 
  • Mortality Following Cardiovascular and Bleeding Events Occurring Beyond 1 Year After Coronary Stenting: A Secondary Analysis of the Dual Antiplatelet Therapy (DAPT) Study. 
  • Mortality and rate of stroke or embolism in atrial fibrillation during long-term follow-up in the embolism in left atrial thrombi (ELAT) study. 
  • Mortality benefit with prasugrel in the TRITON-TIMI 38 coronary artery bypass grafting cohort: risk-adjusted retrospective data analysis. 
  • Moving From Clinical Trials to Precision Medicine: The Role for Predictive Modeling. 
  • NF-kappaB, inflammation and pancreatic carcinogenesis: NF-kappaB as a chemoprevention target (review). 
  • NSAIDs and cognition in Alzheimer's disease. 
  • Nitric oxide binding to human ferrihemoglobins cross-linked between either alpha or beta subunits. 
  • No advantage of A beta 42-lowering NSAIDs for prevention of Alzheimer dementia in six pooled cohort studies. 
  • Nonsteroidal antiinflammatory drugs and risk of gastric adenocarcinoma: the multiethnic cohort study. 
  • Novel platelet antiaggregants and the changing landscape of stroke prevention. 
  • Novel role of platelet reactivity in adverse left ventricular remodelling after ST-segment elevation myocardial infarction: The REMODELING Trial. 
  • Nuclear factor kappa B activation is a potential target for preventing pancreatic carcinoma by aspirin. 
  • Optimal pediatric dosing of anti-platelet agents for pipeline stent embolization -a case report and review of the literature. 
  • Optimizing platelet P2Y12 inhibition for patients undergoing PCI. 
  • Oral glycoprotein IIb/IIIa antagonists: new insights from the SYMPHONY trial. 
  • Oral platelet glycoprotein IIb/IIIa inhibition. 
  • Outcome in elderly patients undergoing primary coronary intervention for acute myocardial infarction: results from the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial. 
  • Outcomes of Patients With Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention Receiving an Oral Anticoagulant and Dual Antiplatelet Therapy: A Comparison of Clopidogrel Versus Prasugrel From the TRANSLATE-ACS Study. 
  • Overestimation of platelet aspirin resistance detection by thrombelastograph platelet mapping and validation by conventional aggregometry using arachidonic acid stimulation. 
  • Oxylipid Profile of Low-Dose Aspirin Exposure: A Pharmacometabolomics Study. 
  • P2Y12 receptor inhibitors for secondary prevention of ischemic stroke. 
  • PA tablets: investigational compounds combining aspirin and omeprazole for cardioprotection. 
  • PA32540 (a coordinated-delivery tablet of enteric-coated aspirin 325 mg and immediate-release omeprazole 40 mg) versus enteric-coated aspirin 325 mg alone in subjects at risk for aspirin-associated gastric ulcers: results of two 6-month, phase 3 studies. 
  • Patient-focused intervention to improve long-term adherence to evidence-based medications: a randomized trial. 
  • Patient-reported frequency of taking aspirin in a population with coronary artery disease. 
  • Patterns of aspirin dosing in non-ST-elevation acute coronary syndromes in the CRUSADE Quality Improvement Initiative. 
  • Percutaneous coronary intervention and antiplatelet therapy in patients with atrial fibrillation receiving apixaban or warfarin: Insights from the ARISTOTLE trial. 
  • Percutaneous coronary intervention in a patient with immune thrombocytopenia purpura. 
  • Peri-procedural platelet function and platelet inhibition in percutaneous coronary intervention. 
  • Perioperative management of a neurosurgical patient requiring antiplatelet therapy. 
  • Peripheral blood gene expression signatures which reflect smoking and aspirin exposure are associated with cardiovascular events. 
  • Persistence of the prothrombotic state after acute coronary syndromes: implications for treatment. 
  • Persistence with secondary prevention medications after acute myocardial infarction: Insights from the TRANSLATE-ACS study. 
  • Pharmacodynamic effects of a new fixed-dose clopidogrel-aspirin combination compared with separate administration of clopidogrel and aspirin in patients treated with coronary stents: The ACCEL-COMBO trial. 
  • Pharmacodynamic efficacy and safety of adjunctive cilostazol loading to clopidogrel and aspirin loading: the results of the ACCEL-LOADING (Accelerated Platelet Inhibition by Cilostazol Loading) study. 
  • Pharmacodynamic evaluation of clopidogrel plus PA32540: the Spaced PA32540 With Clopidogrel Interaction Gauging (SPACING) study. 
  • Phase 1b randomized study of antidote-controlled modulation of factor IXa activity in patients with stable coronary artery disease. 
  • Phosphoaspirin (MDC-43), a novel benzyl ester of aspirin, inhibits the growth of human cancer cell lines more potently than aspirin: a redox-dependent effect. 
  • Plasma prostaglandin F 2-alpha levels in dysmenorrehic women. 
  • Plasma thromboxane and prostacyclin are linear related and increased in patients presenting with acute myocardial infarction. 
  • Platelet Reactivity and Risk of Ischemic Stroke After Coronary Drug-Eluting Stent Implantation: From the ADAPT-DES Study. 
  • Platelet activation after stenting with heparin-coated versus noncoated stents. 
  • Platelet activation in patients with congestive heart failure: do we have enough evidence to consider clopidogrel? 
  • Platelet function and pharmacologic inhibition. 
  • Platelet function measured by VerifyNow identifies generalized high platelet reactivity in aspirin treated patients. 
  • Platelet function monitoring in patients with coronary artery disease. 
  • Platelet inhibition strategies in percutaneous coronary intervention: competition or coopetition? 
  • Platelet inhibitors: what are the data in women? 
  • Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study. 
  • Platelet-related biomarkers and their response to inhibition with aspirin and p2y12-receptor antagonists in patients with acute coronary syndrome. 
  • Pneumatic compression or aspirin prophylaxis against thromboembolism in total hip arthroplasty. 
  • Polymorphisms associated with in vitro aspirin resistance are not associated with clinical outcomes in patients with coronary artery disease who report regular aspirin use. 
  • Post-operative heparin may not be required for transitioning patients with a HeartMate II left ventricular assist system to long-term warfarin therapy. 
  • Postcoronary thrombolysis management. 
  • Postmenopausal hormone use in women with acute coronary syndromes. 
  • Potential impact of evidence-based medicine in acute coronary syndromes: insights from GUSTO-IIb. Global Use of Strategies to Open Occluded Arteries in Acute Coronary Syndromes trial. 
  • Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. 
  • Prasugrel. 
  • Preconceptional counseling and intervention continued. 
  • Prediction of Ischemic and Bleeding Events Using the Dual Antiplatelet Therapy Score in an Unrestricted Percutaneous Coronary Intervention Population. 
  • Predictors of contemporary coronary artery bypass grafting outcomes. 
  • Predictors of recurrent ischemic events and death in unstable coronary artery disease after treatment with combination antithrombotic therapy. 
  • Predictors of stroke in patients paced for sick sinus syndrome. 
  • Prehospital electrocardiograms (ECGs) do not improve the process of emergency department care in hospitals with higher usage of ECGs in non-ST-segment elevation myocardial infarction patients. 
  • Prevalence and management of hypertension in acute coronary syndrome patients varies by sex: observations from the Sibrafiban versus aspirin to Yield Maximum Protection from ischemic Heart events postacute cOroNary sYndromes (SYMPHONY) randomized clinical trials. 
  • Prevalence of aspirin and clopidogrel resistance among patients with and without drug-eluting stent thrombosis. 
  • Primary prevention of stroke. 
  • Primary prevention of stroke. 
  • Prior aspirin use predicts worse outcomes in patients with non-ST-elevation acute coronary syndromes. PURSUIT Investigators. Platelet IIb/IIIa in Unstable angina: Receptor Suppression Using Integrilin Therapy. 
  • Prognostic significance of elevated troponin I after percutaneous coronary intervention. 
  • Prophylaxis of thromboembolism. 
  • Prospective validation of the Bleeding Academic Research Consortium classification in the all-comer PRODIGY trial. 
  • Purine pathway implicated in mechanism of resistance to aspirin therapy: pharmacometabolomics-informed pharmacogenomics. 
  • Quality measures in high-risk pregnancies: Executive Summary of a Cooperative Workshop of the Society for Maternal-Fetal Medicine, National Institute of Child Health and Human Development, and the American College of Obstetricians and Gynecologists. 
  • Quality of medical care and excess mortality in older patients with mental disorders. 
  • Randomisation in the SYMPHONY trial. 
  • Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. 
  • Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II. 
  • Randomized Trial of Lenalidomide Alone Versus Lenalidomide Plus Rituximab in Patients With Recurrent Follicular Lymphoma: CALGB 50401 (Alliance). 
  • Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. 
  • Randomized evaluation of the efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. Long-term results of the Integrilin and Enoxaparin Randomized Assessment of Acute Coronary Syndrome Treatment (INTERACT) trial. 
  • Randomized evaluation of the safety and efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. 
  • Randomized trial of aspirin, sibrafiban, or both for secondary prevention after acute coronary syndromes. 
  • Randomized trial of pulsed corticosteroid therapy for primary treatment of Kawasaki disease. 
  • Randomized trial of warfarin, aspirin, and clopidogrel in patients with chronic heart failure: the Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) trial. 
  • Randomized, double-blind, placebo-controlled, international trial of the oral IIb/IIIa antagonist lotrafiban in coronary and cerebrovascular disease. 
  • Rapid Desensitization of the Patients With Aspirin Hypersensitivity and Coronary Artery Disease. 
  • Rapid assessment of glycoprotein IIb/IIIa blockade with the platelet function analyzer (PFA-100) during percutaneous coronary intervention. 
  • Rapid change in prescribing behavior in hospitals participating in get with the guidelines-stroke after release of the management of atherothrombosis with clopidogrel in high-risk patients (MATCH) clinical trial results. 
  • Rationale and design for the Vascular Outcomes study of ASA along with rivaroxaban in endovascular or surgical limb revascularization for peripheral artery disease (VOYAGER PAD). 
  • Rationale and design of the Japan-USA harmonized assessment by randomized, multicenter study of OrbusNEich's combo StEnt (Japan-USA HARMONEE): Assessment of a novel DES platform for percutaneous coronary revascularization in patients with ischemic coronary disease and non-ST-elevation acute coronary syndrome. 
  • Re: Gender disparity in cardiac procedures and medication use for acute myocardial infarction. 
  • Reduced anticoagulation after mechanical aortic valve replacement: interim results from the prospective randomized on-X valve anticoagulation clinical trial randomized Food and Drug Administration investigational device exemption trial. 
  • Reduced incidence of AD with NSAID but not H2 receptor antagonists: the Cache County Study. 
  • Reduced valve replacement surgery and complication rate in Staphylococcus aureus endocarditis patients receiving acetyl-salicylic acid. 
  • Reducing cardiac events after acute coronary syndromes. 
  • Regular aspirin use and retinal microvascular signs: the Blue Mountains Eye Study. 
  • Relation between aspirin dose, all-cause mortality, and bleeding in patients with recent cerebrovascular or coronary ischemic events (from the BRAVO Trial). 
  • Relation between time of symptom onset of ST-segment elevation myocardial infarction and patient baseline characteristics: from the National Cardiovascular Data Registry. 
  • Relationship Between Arterial Access and Outcomes in ST-Elevation Myocardial Infarction With a Pharmacoinvasive Versus Primary Percutaneous Coronary Intervention Strategy: Insights From the STrategic Reperfusion Early After Myocardial Infarction (STREAM) Study. 
  • Relationship between postoperative clopidogrel use and subsequent angiographic and clinical outcomes following coronary artery bypass grafting. 
  • Relationship of Platelet Reactivity With Bleeding Outcomes During Long-Term Treatment With Dual Antiplatelet Therapy for Medically Managed Patients With Non-ST-Segment Elevation Acute Coronary Syndromes. 
  • Renal insufficiency and heart failure: prognostic and therapeutic implications from a prospective cohort study. 
  • Report from the 100th Cardiovascular and Renal Drugs Advisory Committee meeting: US Food and Drug Administration: December 8-9, 2003 Gaithersburg, MD. 
  • Resistance to antiplatelet drugs: what progress has been made? 
  • Response variability and the role of platelet function testing. 
  • Retinal vein occlusions in patients taking warfarin. 
  • Review of pharmacokinetic and pharmacodynamic modeling and safety of proton pump inhibitors and aspirin. 
  • Review of the 2005 American College of Cardiology, American Heart Association, and Society for Cardiovascular Interventions guidelines for adjunctive pharmacologic therapy during percutaneous coronary interventions: practical implications, new clinical data, and recommended guideline revisions. 
  • Rhythm versus rate control in the contemporary management of atrial fibrillation in-hospital. 
  • Risk factor burden and control at the time of admission in patients with acute myocardial infarction: Results from the NCDR. 
  • Risk factors for cerebrovascular events following fontan palliation in patients with a functional single ventricle. 
  • Risk of stroke associated with abciximab among patients undergoing percutaneous coronary intervention. 
  • Risk stratification in the setting of non-ST elevation acute coronary syndromes 1999-2007. 
  • Risk stratification with a point-of-care cardiac troponin T test in acute myocardial infarction. GUSTOIII Investigators. Global Use of Strategies To Open Occluded Coronary Arteries. 
  • Rivaroxaban versus Clopidogrel for Peripheral Artery Disease: A Clinico-Economic Approach of the COMPASS Trial. 
  • Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. 
  • Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. 
  • Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. 
  • Role of platelet inhibition in microvascular surgery. 
  • ST-Segment recovery adds to the assessment of TIMI 2 and 3 flow in predicting infarct wall motion after thrombolytic therapy. 
  • Safety and Use of Anticoagulation After Aortic Valve Replacement With Bioprostheses: A Meta-Analysis. 
  • Safety and effectiveness of antithrombotic strategies in older adult patients with atrial fibrillation and non-ST elevation myocardial infarction. 
  • Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial. 
  • Sample size requirements and length of study for testing interaction in a 2 x k factorial design when time-to-failure is the outcome [corrected]. 
  • Secondary Prevention of Cardiovascular Disease in Patients With Type 2 Diabetes Mellitus: International Insights From the TECOS Trial (Trial Evaluating Cardiovascular Outcomes With Sitagliptin). 
  • Secondary prevention after coronary artery bypass graft surgery: findings of a national randomized controlled trial and sustained society-led incorporation into practice. 
  • Seeking the optimal aspirin dose in acute coronary syndromes. 
  • Selecting the Duration of Antiplatelet Therapy Following Percutaneous Coronary Intervention: A Complex Decision or Not? 
  • Selective serotonin reuptake inhibitors yield additional antiplatelet protection in patients with congestive heart failure treated with antecedent aspirin. 
  • Sex differences in management and outcomes of patients with stable symptoms suggestive of coronary artery disease: Insights from the PROMISE trial. 
  • Shortened platelet lifespan in patients with hydrocephalus and ventriculojugular shunts: results of preliminary attempts at correction. 
  • Sinusitis: allergies, antibiotics, aspirin, asthma. 
  • Slowed ST segment recovery despite early infarct artery patency in patients with Q waves at presentation with a first acute myocardial infarction. Implications of initial Q waves on myocyte reperfusion. 
  • Smoking, caffeine, and nonsteroidal anti-inflammatory drugs in families with Parkinson disease. 
  • Sodium nitroprusside, an endothelium-derived relaxing factor congener, increases platelet cyclic GMP levels and inhibits epinephrine-exacerbated in vivo platelet thrombus formation in stenosed canine coronary arteries. 
  • Spaced administration of PA32540 and clopidogrel results in greater platelet inhibition than synchronous administration of enteric-coated aspirin and enteric-coated omeprazole and clopidogrel. 
  • Spontaneous MI After Non-ST-Segment Elevation Acute Coronary Syndrome Managed Without Revascularization: The TRILOGY ACS Trial. 
  • Statin therapy and inflammation in patients with diabetes treated with high dose aspirin. 
  • Statin therapy and thromboxane generation in patients with coronary artery disease treated with high-dose aspirin. 
  • Stent Thrombosis and Dual Antiplatelet Therapy Interruption With Everolimus-Eluting Stents: Insights From the Xience V Coronary Stent System Trials. 
  • Stroke in patients with acute coronary syndromes: incidence and outcomes in the platelet glycoprotein IIb/IIIa in unstable angina. Receptor suppression using integrilin therapy (PURSUIT) trial. The PURSUIT Investigators. 
  • Stroke prevention in atrial fibrillation: Closing the gap. 
  • Stroke prevention: the emerging strategies. 
  • Study of the ability of phenacetin, acetaminophen, and aspirin to induce cytotoxicity, mutation, and morphological transformation in C3H/10T1/2 clone 8 mouse embryo cells. 
  • Surgical management of carotid artery atherosclerotic disease. 
  • Sustained sex-based treatment differences in acute coronary syndrome care: Insights from the American Heart Association Get With The Guidelines Coronary Artery Disease Registry. 
  • Sustained ventricular arrhythmias and mortality among patients with acute myocardial infarction: results from the GUSTO-III trial. 
  • Systems Pharmacogenomics Finds RUNX1 Is an Aspirin-Responsive Transcription Factor Linked to Cardiovascular Disease and Colon Cancer. 
  • TIMI IIB follow-up. Lessons for clinicians and investigators. 
  • Temporal trends for secondary prevention measures among patients hospitalized with coronary artery disease. 
  • The ADAPTABLE Trial and Aspirin Dosing in Secondary Prevention for Patients with Coronary Artery Disease. 
  • The Effect of Continued Low Dose Aspirin Therapy in Patients Undergoing Percutaneous Nephrolithotomy. 
  • The Pharmacogenomics of Anti-Platelet Intervention (PAPI) Study: Variation in Platelet Response to Clopidogrel and Aspirin. 
  • The Society of Thoracic Surgeons practice guideline series: aspirin and other antiplatelet agents during operative coronary revascularization (executive summary). 
  • The Strategic Reperfusion Early After Myocardial Infarction (STREAM) study. 
  • The Study of Neurocognitive Outcomes, Radiological and Retinal Effects of Aspirin in Sleep Apnoea- rationale and methodology of the SNORE-ASA study. 
  • The V89L polymorphism in the 5alpha-reductase type 2 gene and risk of prostate cancer. 
  • The Warfarin and Antiplatelet Therapy in Heart Failure trial (WATCH): rationale, design, and baseline patient characteristics. 
  • The coronary artery response to implantation of a balloon-expandable flexible stent in the aspirin- and non-aspirin-treated swine model. 
  • The cost-effectiveness of aspirin for chemoprevention of colorectal cancer. 
  • The effect of active site-inhibited factor VIIa on tissue factor-initiated coagulation using platelets before and after aspirin administration. 
  • The effect of aspirin dosing on platelet function in diabetic and nondiabetic patients: an analysis from the aspirin-induced platelet effect (ASPECT) study. 
  • The effect of aspirin on endothelial progenitor cell biology: preliminary investigation of novel properties. 
  • The effect of elinogrel on high platelet reactivity during dual antiplatelet therapy and the relation to CYP2C19*2 genotype: first experience in patients. 
  • The effect of ticagrelor versus clopidogrel on high on-treatment platelet reactivity: combined analysis of the ONSET/OFFSET and RESPOND studies. 
  • The enigmatic search for optimal DAPT duration. 
  • The failure of orally administered glycoprotein IIb/IIIa inhibitors to prevent recurrent cardiac events. 
  • The genetic response to short-term interventions affecting cardiovascular function: rationale and design of the Heredity and Phenotype Intervention (HAPI) Heart Study. 
  • The influence of CYP2C19 polymorphisms on the pharmacokinetics, pharmacodynamics, and clinical effectiveness of P2Y(12) inhibitors. 
  • The influence of smoking status on the pharmacokinetics and pharmacodynamics of clopidogrel and prasugrel: the PARADOX study. 
  • The perioperative management of antithrombotic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). 
  • The polypill to prevent cardiovascular disease: physicians' perspectives. 
  • The primary and secondary prevention of coronary artery disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). 
  • The problem of persistent platelet activation in acute coronary syndromes and following percutaneous coronary intervention. 
  • The quality of antiplatelet and anticoagulant medication administration among ST-segment elevation myocardial infarction patients transferred for primary percutaneous coronary intervention. 
  • The rationale for and comparisons of different antiplatelet treatments in acute coronary syndrome. 
  • The relation between CYP2C19 genotype and phenotype in stented patients on maintenance dual antiplatelet therapy. 
  • The relation between platelet reactivity and glycemic control in diabetic patients with cardiovascular disease on maintenance aspirin and clopidogrel therapy. 
  • The relationship of platelet reactivity to the occurrence of post-stenting ischemic events: emergence of a new cardiovascular risk factor. 
  • The role of aspirin and dipyridamole on vascular DNA synthesis and intimal hyperplasia following deendothelialization. 
  • The role of aspirin in cardiovascular diseases--forgotten benefits? 
  • The role of prasugrel in the management of acute coronary syndromes: a systematic review. 
  • The stratification of platelet reactivity and activation in patients with stable coronary artery disease on aspirin therapy. 
  • The truth and consequences of the COURAGE trial. 
  • Thrombin-induced platelet-fibrin clot strength: relation to high on-clopidogrel platelet reactivity, genotype, and post-percutaneous coronary intervention outcomes. 
  • Thromboembolism after WATCHMANTM in a clopidogrel non-responder: A case for concern? 
  • Thrombolysis and adjunctive therapy in acute myocardial infarction: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. 
  • Ticagrelor Use in Acute Myocardial Infarction: Insights From the National Cardiovascular Data Registry. 
  • Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial. 
  • Ticagrelor in Peripheral Artery Disease Endovascular Revascularization (TI-PAD): Challenges in clinical trial execution. 
  • Ticagrelor with aspirin or alone in high-risk patients after coronary intervention: Rationale and design of the TWILIGHT study. 
  • Ticagrelor with or without Aspirin in High-Risk Patients after PCI. 
  • Ticlopidine versus aspirin after myocardial infarction (STAMI) trial. 
  • Ticlopidine-associated pancytopenia: implications of an acetylsalicylic acid alternative. 
  • Time dependence of clopidogrel loading effect: platelet activation versus platelet aggregation. 
  • Time-dependent changes in non-COX-1-dependent platelet function with daily aspirin therapy. 
  • Timing of death and myocardial infarction in patients with non-ST elevation acute coronary syndromes: insights from randomized clinical trials. 
  • Tissue plasminogen activator for acute ischemic stroke. 
  • Treatment Effect of Clopidogrel Plus Aspirin Within 12 Hours of Acute Minor Stroke or Transient Ischemic Attack. 
  • Treatment disparities in the care of patients with and without diabetes presenting with non-ST-segment elevation acute coronary syndromes. 
  • Treatment of blister-like aneurysms with the pipeline embolization device. 
  • Treatment of patients with myocardial infarction who present with a paced rhythm. 
  • Treatment strategies in non-ST-elevation acute coronary syndromes in patients undergoing percutaneous coronary intervention: an evidence-based review of clinical trial results and treatment guidelines: report on a roundtable discussion. 
  • Trends in the use of evidence-based treatments for coronary artery disease among women and the elderly: findings from the get with the guidelines quality-improvement program. 
  • Triple antithrombotic therapy with prasugrel in the stented patient: concern for more bleeding. 
  • Triple vs Dual Antithrombotic Therapy in Patients with Atrial Fibrillation and Coronary Artery Disease. 
  • Troponin T levels in patients with acute coronary syndromes, with or without renal dysfunction. 
  • Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. 
  • US National Survey of Physician Practices for the Secondary and Tertiary Prevention of Ischemic Stroke. Medical therapy in patients with carotid artery stenosis. 
  • US national survey of physician practices for the secondary and tertiary prevention of ischemic stroke. Design, service availability, and common practices. 
  • Underuse of aspirin in a referral population with documented coronary artery disease. 
  • Uniform platelet activation exists before coronary stent implantation despite aspirin therapy. 
  • Update to the AHA/ASA recommendations for the prevention of stroke in patients with stroke and transient ischemic attack. 
  • Use and Outcomes of Triple Therapy Among Older Patients With Acute Myocardial Infarction and Atrial Fibrillation. 
  • Use and associated risks of concomitant aspirin therapy with oral anticoagulation in patients with atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry. 
  • Use of aspirin and ibuprofen compared with aspirin alone and the risk of myocardial infarction. 
  • Use of aspirin associates with longer primary patency of hemodialysis grafts. 
  • Use of common analgesic medications and ovarian cancer survival: results from a pooled analysis in the Ovarian Cancer Association Consortium. 
  • Use of common antiplatelet drugs for vascular diseases. 
  • Use of concomitant aspirin in patients with atrial fibrillation: Findings from the ROCKET AF trial. 
  • Use of evidence-based medical therapy in patients undergoing percutaneous coronary revascularization in the United States, Europe, and Canada. Coronary Angioplasty Versus Excisional Atherectomy Trial (CAVEAT-I) and Canadian Coronary Atherectomy Trial (CCAT) investigators. 
  • Use of evidence-based medicine for acute coronary syndromes in the elderly and very elderly: insights from the Sibrafiban vs aspirin to Yield Maximum Protection from ischemic Heart events postacute cOroNary sYndromes trials. 
  • Use of online promotion to encourage patient awareness of aspirin use to prevent heart attack and stroke. 
  • Utilization of secondary prevention therapies in patients with nonobstructive coronary artery disease identified during cardiac catheterization: insights from the National Cardiovascular Data Registry Cath-PCI Registry. 
  • Vale, warfarin: a stentorian farewell. 
  • Vale, warfarin: a stentorian farewell. 
  • Variation in warfarin thromboprophylaxis after mitral valve repair: does equipoise exist and is a randomized trial warranted? 
  • Venous thromboembolism prophylaxis and treatment in patients with cancer: american society of clinical oncology clinical practice guideline update 2014. 
  • Vorapaxar and diplopia: Possible off-target PAR-receptor mismodulation. 
  • Warfarin and Aspirin Versus Warfarin Alone for Prevention of Embolic Events in Patients with a HeartMate II Left Ventricular Assist Device. 
  • Warfarin therapy does not increase bleeding in patients undergoing heart transplantation. 
  • Watching the WATCH trial: the role of sponsors and data monitoring committees. 
  • [Livedoid vasculopathy with heterozygous factor V Leiden mutation and sticky platelet syndrome]. 
• 

  Keywords of People

  • Alexander, John Hunter Peel, Professor of Medicine, Medicine, Cardiology
  • Granger, Christopher Bull, Professor of Medicine, School of Nursing
  • Laskowitz, Daniel Todd, Professor of Neurology, Duke Innovation & Entrepreneurship
  • Middleton, John Paul, Associate Professor of Medicine, Medicine, Nephrology
  • Muir, Kelly Walton, Associate Professor of Ophthalmology, Ophthalmology, Glaucoma
  • O'Connor, Christopher Michael, Richard Sean Stack, M.D. / Guidant Foundation Distinguished Professor of Cardiology, Medicine, Clinical Pharmacology